Tysabri Could Return To Market As “Niche” Drug, Analyst Says

Morgan Stanley report predicts sales of $500 mil. for Biogen Idec/Elan’s multiple sclerosis therapy if it returns to market. Analyst’s review shows additional safety signals.

More from Archive

More from Pink Sheet